메뉴 건너뛰기




Volumn 70, Issue 13, 2013, Pages 1123-1131

Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; METFORMIN; MICROSPHERE; PIOGLITAZONE; POLYGLACTIN; SITAGLIPTIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; DELAYED RELEASE FORMULATION; GLARGINE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; LONG ACTING INSULIN; PEPTIDE; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE; VENOM;

EID: 84891382656     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp120168     Document Type: Article
Times cited : (14)

References (62)
  • 1
    • 84879556643 scopus 로고    scopus 로고
    • San Diego, CA: Amylin Pharmaceuticals
    • Byetta (exenatide) package insert. San Diego, CA: Amylin Pharmaceuticals; 2011.
    • (2011) Byetta (Exenatide) Package Insert
  • 2
    • 34248223285 scopus 로고    scopus 로고
    • Biology of incretins: GLP-1 and GIP
    • Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007; 132:2131-57.
    • (2007) Gastroenterology , vol.132 , pp. 2131-2157
    • Baggio, L.L.1    Drucker, D.J.2
  • 4
  • 5
    • 0018758893 scopus 로고
    • The incretin concept today
    • Creutzfeldt W. The incretin concept today. Diabetologia. 1979; 16:75-85.
    • (1979) Diabetologia , vol.16 , pp. 75-85
    • Creutzfeldt, W.1
  • 6
    • 0022461548 scopus 로고
    • Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses
    • Nauck MA, Homberger E, Siegel EG et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986; 63:492-8.
    • (1986) J Clin Endocrinol Metab , vol.63 , pp. 492-498
    • Nauck, M.A.1    Homberger, E.2    Siegel, E.G.3
  • 7
    • 0033766716 scopus 로고    scopus 로고
    • Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide
    • Deacon CF, Nauck MA, Meier J et al. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab. 2000; 85:3575-81.
    • (2000) J Clin Endocrinol Metab , vol.85 , pp. 3575-3581
    • Deacon, C.F.1    Nauck, M.A.2    Meier, J.3
  • 8
    • 2942670571 scopus 로고    scopus 로고
    • Recombinant human chorionic gonadotropin but not dihydrotestosterone alone stimulates osteoblastic collagen synthesis in older men with partial age-related androgen deficiency
    • Meier C, Liu PY, Ly LP et al. Recombinant human chorionic gonadotropin but not dihydrotestosterone alone stimulates osteoblastic collagen synthesis in older men with partial age-related androgen deficiency. J Clin Endocrinol Metab. 2004;89:3033-41.
    • (2004) J Clin Endocrinol Metab , vol.89 , pp. 3033-3041
    • Meier, C.1    Liu, P.Y.2    Ly, L.P.3
  • 9
    • 33751506355 scopus 로고    scopus 로고
    • The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects
    • Vilsboll T, Agerso H, Lauritsen T et al. The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects. Regul Pept. 2006;137:168-72.
    • (2006) Regul Pept , vol.137 , pp. 168-172
    • Vilsboll, T.1    Agerso, H.2    Lauritsen, T.3
  • 10
    • 0018193765 scopus 로고
    • Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) in man
    • Buchan AM, Polak JM, Capella C et al. Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) in man. Histochemistry. 1978; 56:37-44.
    • (1978) Histochemistry , vol.56 , pp. 37-44
    • Buchan, A.M.1    Polak, J.M.2    Capella, C.3
  • 12
    • 0033520869 scopus 로고    scopus 로고
    • GIP biology and fat metabolism
    • Yip RG, Wolfe MM. GIP biology and fat metabolism. Life Sci. 2000; 66:91-103.
    • (2000) Life Sci , vol.66 , pp. 91-103
    • Yip, R.G.1    Wolfe, M.M.2
  • 13
    • 0028803336 scopus 로고
    • Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects
    • Deacon CF, Nauck MA, Toft-Nielsen M et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995; 44:1126-31.
    • (1995) Diabetes , vol.44 , pp. 1126-1131
    • Deacon, C.F.1    Nauck, M.A.2    Toft-Nielsen, M.3
  • 14
    • 0141446228 scopus 로고    scopus 로고
    • Enhancing incretin action for the treatment of type 2 diabetes
    • Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003; 26:2929-40.
    • (2003) Diabetes Care , vol.26 , pp. 2929-2940
    • Drucker, D.J.1
  • 15
    • 84930476726 scopus 로고    scopus 로고
    • Anti-inflammatory properties of exenatide in human pancreatic cells
    • Cechin SR, Perez-Alvarez I, Fenjves E et al. Anti-inflammatory properties of exenatide in human pancreatic cells. Cell Transplant. 2012; 21:633-48.
    • (2012) Cell Transplant , vol.21 , pp. 633-648
    • Cechin, S.R.1    Perez-Alvarez, I.2    Fenjves, E.3
  • 16
    • 74049087761 scopus 로고    scopus 로고
    • Liraglutide induces cell proliferation and protects from interleukin-1beta induced beta-cell apoptosis in human islets
    • Abstract
    • Prazak R, Rütti S, Ellingsgaard H et al. Liraglutide induces cell proliferation and protects from interleukin-1beta induced beta-cell apoptosis in human islets. Diabetes. 2008; 57(suppl 1):1573-P. Abstract.
    • (2008) Diabetes , vol.57 , pp. 1573-P
    • Prazak, R.1    Rütti, S.2    Ellingsgaard, H.3
  • 17
    • 39749143348 scopus 로고    scopus 로고
    • Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus
    • Vilsbøll T, Brock B, Perrild H et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus. Diabet Med. 2008; 25:152-6.
    • (2008) Diabet Med , vol.25 , pp. 152-156
    • Vilsbøll, T.1    Brock, B.2    Perrild, H.3
  • 18
    • 27744541052 scopus 로고    scopus 로고
    • Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes
    • Fehse F, Trautmann M, Holst JJ et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2005; 90:5991-7.
    • (2005) J Clin Endocrinol Metab , vol.90 , pp. 5991-5997
    • Fehse, F.1    Trautmann, M.2    Holst, J.J.3
  • 19
    • 85077296846 scopus 로고    scopus 로고
    • Effects of exenatide on palmitate-induced inflammation and insulin resistance in skeletal muscle
    • Abstract
    • Sinha S, Sathyanarayana P, Jogi M et al. Effects of exenatide on palmitate-induced inflammation and insulin resistance in skeletal muscle. Diabetes. 2008; 57(suppl 1):1266-P. Abstract.
    • (2008) Diabetes , vol.57 , pp. 1266-P
    • Sinha, S.1    Sathyanarayana, P.2    Jogi, M.3
  • 20
    • 63249084223 scopus 로고    scopus 로고
    • Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver
    • Zheng D, Ionut V, Mooradian AD et al. Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver. Diabetes. 2009; 58:352-9.
    • (2009) Diabetes , vol.58 , pp. 352-359
    • Zheng, D.1    Ionut, V.2    Mooradian, A.D.3
  • 21
    • 0038497464 scopus 로고    scopus 로고
    • Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes
    • Kolterman OG, Buse JB, Fineman MS et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003; 88:3082-9.
    • (2003) J Clin Endocrinol Metab , vol.88 , pp. 3082-3089
    • Kolterman, O.G.1    Buse, J.B.2    Fineman, M.S.3
  • 22
    • 33644618433 scopus 로고    scopus 로고
    • The biology of incretin hormones
    • Drucker DJ. The biology of incretin hormones. Cell Metab. 2006; 3:153-65.
    • (2006) Cell Metab , vol.3 , pp. 153-165
    • Drucker, D.J.1
  • 23
    • 1442311383 scopus 로고    scopus 로고
    • Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
    • Nikolaidis LA, Mankad S, Sokos GG et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004; 109:962-5.
    • (2004) Circulation , vol.109 , pp. 962-965
    • Nikolaidis, L.A.1    Mankad, S.2    Sokos, G.G.3
  • 24
    • 33845293219 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure
    • Sokos GG, Nikolaidis LA, Mankad S et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006; 12:694.
    • (2006) J Card Fail , vol.12 , pp. 694
    • Sokos, G.G.1    Nikolaidis, L.A.2    Mankad, S.3
  • 25
    • 0026795135 scopus 로고
    • Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4
    • Raufman JP, Singh G, Eng J. Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4. J Biol Chem. 1992; 267:21432-7.
    • (1992) J Biol Chem , vol.267 , pp. 21432-21437
    • Raufman, J.P.1    Singh, G.2    Eng, J.3
  • 26
    • 0033151448 scopus 로고    scopus 로고
    • Factors affecting the degradation rate of poly (lactide-co-glycolide) microspheres in vivo and in vitro
    • Tracy MA, Ward KL, Firouzabadian L et al. Factors affecting the degradation rate of poly (lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials. 1999; 20:1057-62.
    • (1999) Biomaterials , vol.20 , pp. 1057-1062
    • Tracy, M.A.1    Ward, K.L.2    Firouzabadian, L.3
  • 27
    • 78649911161 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing
    • Fineman M, Flanagan S, Taylor K et al. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet. 2011; 50:65-74.
    • (2011) Clin Pharmacokinet , vol.50 , pp. 65-74
    • Fineman, M.1    Flanagan, S.2    Taylor, K.3
  • 28
    • 34249891874 scopus 로고    scopus 로고
    • Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes
    • Kim D, MacConell L, Zhuang D et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007; 30:1487-93.
    • (2007) Diabetes Care , vol.30 , pp. 1487-1493
    • Kim, D.1    MacConell, L.2    Zhuang, D.3
  • 29
    • 73549096393 scopus 로고    scopus 로고
    • Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes
    • Iwamoto K, Nasu R, Yamamura A et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes. Endocr J. 2009; 56:951-62.
    • (2009) Endocr J , vol.56 , pp. 951-962
    • Iwamoto, K.1    Nasu, R.2    Yamamura, A.3
  • 30
    • 77953828230 scopus 로고    scopus 로고
    • DURATION-1: Exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks
    • Buse JB, Drucker DJ, Taylor KL et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care. 2010; 33:1255-61.
    • (2010) Diabetes Care , vol.33 , pp. 1255-1261
    • Buse, J.B.1    Drucker, D.J.2    Taylor, K.L.3
  • 31
    • 53249142132 scopus 로고    scopus 로고
    • Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study
    • Drucker DJ, Buse JB, Taylor K et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008; 372:1240-50.
    • (2008) Lancet , vol.372 , pp. 1240-1250
    • Drucker, D.J.1    Buse, J.B.2    Taylor, K.3
  • 32
    • 79958268386 scopus 로고    scopus 로고
    • Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years
    • Taylor K, Gurney K, Han J et al. Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocr Disord. 2011; 11:9.
    • (2011) BMC Endocr Disord , vol.11 , pp. 9
    • Taylor, K.1    Gurney, K.2    Han, J.3
  • 33
    • 77955573674 scopus 로고    scopus 로고
    • Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial
    • Bergenstal RM, Wysham C, Macconell L et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010; 376:431-9.
    • (2010) Lancet , vol.376 , pp. 431-439
    • Bergenstal, R.M.1    Wysham, C.2    Macconell, L.3
  • 34
    • 79955960213 scopus 로고    scopus 로고
    • DURATION-2: Efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide
    • Wysham C, Bergenstal R, Malloy J et al. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med. 2011; 28:705-14.
    • (2011) Diabet Med , vol.28 , pp. 705-714
    • Wysham, C.1    Bergenstal, R.2    Malloy, J.3
  • 35
    • 77953859640 scopus 로고    scopus 로고
    • Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): An open-label randomised trial
    • Diamant M, Van Gaal L, Stranks S et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010; 375:2234-43.
    • (2010) Lancet , vol.375 , pp. 2234-2243
    • Diamant, M.1    Van Gaal, L.2    Stranks, S.3
  • 36
    • 84859013614 scopus 로고    scopus 로고
    • Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): A 26-week double-blind study
    • Russell-Jones D, Cuddihy RM, Hanefeld M et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care. 2012; 35:252-8.
    • (2012) Diabetes Care , vol.35 , pp. 252-258
    • Russell-Jones, D.1    Cuddihy, R.M.2    Hanefeld, M.3
  • 37
    • 79955661908 scopus 로고    scopus 로고
    • DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes
    • Blevins T, Pullman J, Malloy J et al. DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011; 96:1301-10.
    • (2011) J Clin Endocrinol Metab , vol.96 , pp. 1301-1310
    • Blevins, T.1    Pullman, J.2    Malloy, J.3
  • 38
    • 78649337330 scopus 로고    scopus 로고
    • Improved diabetes treatment satisfaction and weight-related quality of life with both exenatide once weekly and twice daily
    • Kim T, Boye KS, Wintle M et al. Improved diabetes treatment satisfaction and weight-related quality of life with both exenatide once weekly and twice daily. Diabetes. 2008; 57(suppl 1):494-P.
    • (2008) Diabetes , vol.57 , pp. 494-P
    • Kim, T.1    Boye, K.S.2    Wintle, M.3
  • 39
    • 77956076972 scopus 로고    scopus 로고
    • Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents
    • Buse JB, Sesti G, Schmidt WE et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care. 2010; 33:1300-3.
    • (2010) Diabetes Care , vol.33 , pp. 1300-1303
    • Buse, J.B.1    Sesti, G.2    Schmidt, W.E.3
  • 41
    • 79959559653 scopus 로고    scopus 로고
    • Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
    • Elashoff M, Matveyenko AV, Gier B et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011; 141:150-6.
    • (2011) Gastroenterology , vol.141 , pp. 150-156
    • Elashoff, M.1    Matveyenko, A.V.2    Gier, B.3
  • 42
    • 79951704452 scopus 로고    scopus 로고
    • Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: A retrospective observational pharmacy claims analysis
    • Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care. 2010; 33:2349-54.
    • (2010) Diabetes Care , vol.33 , pp. 2349-2354
    • Garg, R.1    Chen, W.2    Pendergrass, M.3
  • 43
    • 79954994764 scopus 로고    scopus 로고
    • A cohort study of acute pancreatitis in relation to exenatide use
    • Dore DD, Bloomgren GL, Wenten M et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab. 2011; 13:559-66.
    • (2011) Diabetes Obes Metab , vol.13 , pp. 559-566
    • Dore, D.D.1    Bloomgren, G.L.2    Wenten, M.3
  • 44
    • 38549162147 scopus 로고    scopus 로고
    • Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
    • Klonoff DC, Buse JB, Nielsen LL. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008; 24:275-86.
    • (2008) Curr Med Res Opin , vol.24 , pp. 275-286
    • Klonoff, D.C.1    Buse, J.B.2    Nielsen, L.L.3
  • 45
    • 78149447857 scopus 로고    scopus 로고
    • Application of adult-learning principles to patient instructions: A usability study for an exenatide once-weekly injection device
    • Lorenzi G, Schreiner B, Osther J et al. Application of adult-learning principles to patient instructions: a usability study for an exenatide once-weekly injection device. Clin Diabetes. 2010; 28:157-62.
    • (2010) Clin Diabetes , vol.28 , pp. 157-162
    • Lorenzi, G.1    Schreiner, B.2    Osther, J.3
  • 46
    • 84866268783 scopus 로고    scopus 로고
    • Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    • Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35:1364-79.
    • (2012) Diabetes Care , vol.35 , pp. 1364-1379
    • Inzucchi, S.E.1    Bergenstal, R.M.2    Buse, J.B.3
  • 47
    • 80054090833 scopus 로고    scopus 로고
    • Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes
    • Bunck MC, Corner A, Eliasson B et al. Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care. 2011; 34:2041-7.
    • (2011) Diabetes Care , vol.34 , pp. 2041-2047
    • Bunck, M.C.1    Corner, A.2    Eliasson, B.3
  • 48
    • 65949122087 scopus 로고    scopus 로고
    • One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: A randomized, controlled trial
    • Bunck MC, Diamant M, Corner A et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2009; 32:762-8.
    • (2009) Diabetes Care , vol.32 , pp. 762-768
    • Bunck, M.C.1    Diamant, M.2    Corner, A.3
  • 49
    • 69249204299 scopus 로고    scopus 로고
    • β-cell function and glycemic control following one year exenatide therapy, and after 12 week wash out, in patients with type 2 diabetes
    • Bunck MC, Diamant M, Corner A et al. β-cell function and glycemic control following one year exenatide therapy, and after 12 week wash out, in patients with type 2 diabetes. Diabetes. 2008; 57(suppl 1):104-OR.
    • (2008) Diabetes , vol.57 , pp. 104-OR
    • Bunck, M.C.1    Diamant, M.2    Corner, A.3
  • 50
    • 0042166232 scopus 로고    scopus 로고
    • Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(1c)
    • Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003; 26:881-5.
    • (2003) Diabetes Care , vol.26 , pp. 881-885
    • Monnier, L.1    Lapinski, H.2    Colette, C.3
  • 51
    • 33846706458 scopus 로고    scopus 로고
    • The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes
    • Monnier L, Colette C, Dunseath GJ et al. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care. 2007; 30:263-9.
    • (2007) Diabetes Care , vol.30 , pp. 263-269
    • Monnier, L.1    Colette, C.2    Dunseath, G.J.3
  • 52
    • 67649774247 scopus 로고    scopus 로고
    • Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily
    • Best JH, Boye KS, Rubin RR et al. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabet Med. 2009; 26:722-8.
    • (2009) Diabet Med , vol.26 , pp. 722-728
    • Best, J.H.1    Boye, K.S.2    Rubin, R.R.3
  • 53
    • 79951689950 scopus 로고    scopus 로고
    • Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment
    • Best JH, Rubin RR, Peyrot M et al. Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment. Diabetes Care. 2011; 34:314-9.
    • (2011) Diabetes Care , vol.34 , pp. 314-319
    • Best, J.H.1    Rubin, R.R.2    Peyrot, M.3
  • 54
    • 0017360990 scopus 로고
    • The measurement of observer agreement for categorical data
    • Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977; 33:159-74.
    • (1977) Biometrics , vol.33 , pp. 159-174
    • Landis, J.R.1    Koch, G.G.2
  • 55
    • 84871048865 scopus 로고    scopus 로고
    • Thomson Reuters. Red book online. www.thomsonhc.com (accessed 2013 Apr 30).
    • Red Book Online
  • 56
    • 79956104536 scopus 로고    scopus 로고
    • Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK
    • Beaudet A, Palmer JL, Timlin L et al. Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK. J Med Econ. 2011; 14:357-66.
    • (2011) J Med Econ , vol.14 , pp. 357-366
    • Beaudet, A.1    Palmer, J.L.2    Timlin, L.3
  • 57
    • 84864705670 scopus 로고    scopus 로고
    • Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: A simulation analysis
    • Gaebler JA, Soto-Campos G, Alperin P et al. Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis. Vasc Health Risk Manag. 2012; 8:255-64.
    • (2012) Vasc Health Risk Manag , vol.8 , pp. 255-264
    • Gaebler, J.A.1    Soto-Campos, G.2    Alperin, P.3
  • 58
    • 84864661021 scopus 로고    scopus 로고
    • Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US
    • Samyshkin Y, Guillermin AL, Best JH, et al. Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US. J MedEcon. 2012; 15(suppl 2):6-13.
    • (2012) J MedEcon , vol.15 , pp. 6-13
    • Samyshkin, Y.1    Guillermin, A.L.2    Best, J.H.3
  • 59
    • 84866144740 scopus 로고    scopus 로고
    • Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): Results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study
    • Inagaki N, Atsumi Y, Oura T, et al. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study. Clin Ther. 2012; 34:1892-908.
    • (2012) Clin Ther , vol.34 , pp. 1892-1908
    • Inagaki, N.1    Atsumi, Y.2    Oura, T.3
  • 60
    • 84872084453 scopus 로고    scopus 로고
    • Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A randomised, open-label study
    • Buse JB, Nauck M, Forst T et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013; 381:117-24.
    • (2013) Lancet , vol.381 , pp. 117-124
    • Buse, J.B.1    Nauck, M.2    Forst, T.3
  • 61
    • 84867344249 scopus 로고    scopus 로고
    • Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years
    • Norwood P, Liutkus JF, Haber H et al. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years. Clin Ther. 2012; 34:2082-90.
    • (2012) Clin Ther , vol.34 , pp. 2082-2090
    • Norwood, P.1    Liutkus, J.F.2    Haber, H.3
  • 62
    • 84877020930 scopus 로고    scopus 로고
    • Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus (2)
    • Cui YM, Guo XH, Zhang DM et al. Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus (2). J Diabetes. 2013; 5:127-35.
    • (2013) J Diabetes , vol.5 , pp. 127-135
    • Cui, Y.M.1    Guo, X.H.2    Zhang, D.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.